Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
RBC Capital Markets downgraded 89Bio Inc ETNB, a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for liver and cardio-metabolic diseases. The analyst maintains a positive outlook on the long-term prospects of the FGF21 class drugs, considering it as a…
#rbccapitalmarkets #89bioincetnb #nash #rbccapital #etnb #fda #glp1 #rbc #sectorperform